Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch Event
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced a live video webcast presentation on January 17, 2023, at 11:00 AM ET. Russ Trenary, President and CEO, will discuss the company's efforts to develop ONS-5010, the first FDA-approved ophthalmic formulation of bevacizumab for retinal conditions, including wet AMD. The FDA has set a PDUFA goal date of August 29, 2023, for this submission. The company has strategic agreements with AmerisourceBergen for commercialization and distribution services.
- None.
- None.
Live video webcast presentation on Tuesday, January 17th at 11:00 AM ET
ISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 11:00 AM ET.
A live video webcast of the presentation will be available on the Events page of the Investors section of Outlook Therapeutics’ website (outlooktherapeutics.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. The FDA accepted Outlook Therapeutics’ BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023. The submission is supported by Outlook Therapeutics’ wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, and other markets. As part of the Company’s multi-year commercial planning process, and in anticipation of potential FDA approval in August 2023, Outlook Therapeutics and AmerisourceBergen have entered into a strategic commercialization agreement to expand the Company’s reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services in the United States. For more information, please visit www.outlooktherapeutics.com.
CONTACTS:
Media Inquiries:
Anna Army
Account Supervisor
LaVoie Health Science
T: 617-351-0246
aarmy@lavoiehealthscience.com
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When is the live webcast presentation for Outlook Therapeutics?
What is ONS-5010 and its significance?
What is the PDUFA goal date for Outlook Therapeutics' BLA submission?
Who is presenting at the Virtual Investor 2023 Companies to Watch Event?
What role does AmerisourceBergen play for Outlook Therapeutics?
